Cargando…

A novel circulating biomarker lnc‐MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events

OBJECTIVE: Long noncoding RNA MALAT1 (lnc‐MALAT1) modulates atherosclerotic progression, myocardial ischemia injury, and systematic inflammation, which may be closely involved in acute myocardial infarction (AMI) pathogenesis. Thus, the current study intended to explore the relationship of lnc‐MALAT...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ruirui, Jin, Jin, Liu, Enxiang, Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757019/
https://www.ncbi.nlm.nih.gov/pubmed/36378551
http://dx.doi.org/10.1002/jcla.24771
_version_ 1784851742338318336
author Li, Ruirui
Jin, Jin
Liu, Enxiang
Zhang, Jun
author_facet Li, Ruirui
Jin, Jin
Liu, Enxiang
Zhang, Jun
author_sort Li, Ruirui
collection PubMed
description OBJECTIVE: Long noncoding RNA MALAT1 (lnc‐MALAT1) modulates atherosclerotic progression, myocardial ischemia injury, and systematic inflammation, which may be closely involved in acute myocardial infarction (AMI) pathogenesis. Thus, the current study intended to explore the relationship of lnc‐MALAT1 to disease risk, features, cytokines, and prognostication in AMI patients. METHODS: This multicenter study consecutively enrolled 160 newly diagnosed AMI patients and 50 controls (angina pectoris patients). Their peripheral blood mononuclear cells were obtained to measure lnc‐MALAT1 by RT–qPCR. Serum cytokines in AMI patients were detected by ELISA. In addition, AMI patients were followed up for major adverse cardiovascular event (MACE) risk evaluation. RESULTS: Lnc‐MALAT1 was higher in AMI patients than in controls (median: 2.245 vs. 0.996, p = 0.004), and it also presented a good capacity for differentiating AMI patients from controls with an area under the curve of 0.823. Lnc‐MALAT1 was positively related to C‐reactive protein (p = 0.005), low‐density lipoprotein cholesterol (p = 0.022), cardiac troponin I (p = 0.021), and infarct size (p = 0.007), but not other biochemical indexes in AMI patients. Meanwhile, lnc‐MALAT1 was positively associated with tumor necrosis factor‐alpha (p = 0.001), interleukin (IL)‐6 (p = 0.031), IL‐17A (p = 0.042), vascular cell adhesion molecule‐1 (p = 0.004), and intercellular adhesion molecule‐1 (p = 0.021) among AMI patients. Importantly, after categorization, lnc‐MALAT1 high (vs. low) was related to an elevated MACE accumulation rate (p = 0.035); furthermore, a higher lnc‐MALAT1 quartile showed a trend to be linked with an increased MACE accumulation rate (p = 0.092). CONCLUSION: Lnc‐MALAT1 may serve as a biomarker for AMI risk, infarct size, inflammation and prognosis, but further validation by large‐scale studies is needed.
format Online
Article
Text
id pubmed-9757019
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97570192022-12-20 A novel circulating biomarker lnc‐MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events Li, Ruirui Jin, Jin Liu, Enxiang Zhang, Jun J Clin Lab Anal Research Articles OBJECTIVE: Long noncoding RNA MALAT1 (lnc‐MALAT1) modulates atherosclerotic progression, myocardial ischemia injury, and systematic inflammation, which may be closely involved in acute myocardial infarction (AMI) pathogenesis. Thus, the current study intended to explore the relationship of lnc‐MALAT1 to disease risk, features, cytokines, and prognostication in AMI patients. METHODS: This multicenter study consecutively enrolled 160 newly diagnosed AMI patients and 50 controls (angina pectoris patients). Their peripheral blood mononuclear cells were obtained to measure lnc‐MALAT1 by RT–qPCR. Serum cytokines in AMI patients were detected by ELISA. In addition, AMI patients were followed up for major adverse cardiovascular event (MACE) risk evaluation. RESULTS: Lnc‐MALAT1 was higher in AMI patients than in controls (median: 2.245 vs. 0.996, p = 0.004), and it also presented a good capacity for differentiating AMI patients from controls with an area under the curve of 0.823. Lnc‐MALAT1 was positively related to C‐reactive protein (p = 0.005), low‐density lipoprotein cholesterol (p = 0.022), cardiac troponin I (p = 0.021), and infarct size (p = 0.007), but not other biochemical indexes in AMI patients. Meanwhile, lnc‐MALAT1 was positively associated with tumor necrosis factor‐alpha (p = 0.001), interleukin (IL)‐6 (p = 0.031), IL‐17A (p = 0.042), vascular cell adhesion molecule‐1 (p = 0.004), and intercellular adhesion molecule‐1 (p = 0.021) among AMI patients. Importantly, after categorization, lnc‐MALAT1 high (vs. low) was related to an elevated MACE accumulation rate (p = 0.035); furthermore, a higher lnc‐MALAT1 quartile showed a trend to be linked with an increased MACE accumulation rate (p = 0.092). CONCLUSION: Lnc‐MALAT1 may serve as a biomarker for AMI risk, infarct size, inflammation and prognosis, but further validation by large‐scale studies is needed. John Wiley and Sons Inc. 2022-11-15 /pmc/articles/PMC9757019/ /pubmed/36378551 http://dx.doi.org/10.1002/jcla.24771 Text en © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Li, Ruirui
Jin, Jin
Liu, Enxiang
Zhang, Jun
A novel circulating biomarker lnc‐MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events
title A novel circulating biomarker lnc‐MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events
title_full A novel circulating biomarker lnc‐MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events
title_fullStr A novel circulating biomarker lnc‐MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events
title_full_unstemmed A novel circulating biomarker lnc‐MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events
title_short A novel circulating biomarker lnc‐MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events
title_sort novel circulating biomarker lnc‐malat1 for acute myocardial infarction: its relationship with disease risk, features, cytokines, and major adverse cardiovascular events
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757019/
https://www.ncbi.nlm.nih.gov/pubmed/36378551
http://dx.doi.org/10.1002/jcla.24771
work_keys_str_mv AT liruirui anovelcirculatingbiomarkerlncmalat1foracutemyocardialinfarctionitsrelationshipwithdiseaseriskfeaturescytokinesandmajoradversecardiovascularevents
AT jinjin anovelcirculatingbiomarkerlncmalat1foracutemyocardialinfarctionitsrelationshipwithdiseaseriskfeaturescytokinesandmajoradversecardiovascularevents
AT liuenxiang anovelcirculatingbiomarkerlncmalat1foracutemyocardialinfarctionitsrelationshipwithdiseaseriskfeaturescytokinesandmajoradversecardiovascularevents
AT zhangjun anovelcirculatingbiomarkerlncmalat1foracutemyocardialinfarctionitsrelationshipwithdiseaseriskfeaturescytokinesandmajoradversecardiovascularevents
AT liruirui novelcirculatingbiomarkerlncmalat1foracutemyocardialinfarctionitsrelationshipwithdiseaseriskfeaturescytokinesandmajoradversecardiovascularevents
AT jinjin novelcirculatingbiomarkerlncmalat1foracutemyocardialinfarctionitsrelationshipwithdiseaseriskfeaturescytokinesandmajoradversecardiovascularevents
AT liuenxiang novelcirculatingbiomarkerlncmalat1foracutemyocardialinfarctionitsrelationshipwithdiseaseriskfeaturescytokinesandmajoradversecardiovascularevents
AT zhangjun novelcirculatingbiomarkerlncmalat1foracutemyocardialinfarctionitsrelationshipwithdiseaseriskfeaturescytokinesandmajoradversecardiovascularevents